Generic Drugs

First tentative approval for generic, MetroGel, received

Published in Medical Letter on the CDC and FDA, October 23rd, 2005

Fougera, a specialty manufacturer of dermatologic and ophthalmic pharmaceuticals, announced that it has received tentative U.S. Food & Drug Administration (FDA) approval to introduce the first generic version of Metronidazole Topical Gel USP 0.75%.

The patent on the branded product by Galderma expires on June 6, 2006.

MetroGel generated approximately $75 million in sales in 2004. It is indicated for the treatment of rosacea.

MetroGel represents the eighth FDA approval and the third first-generic for Fougera thus far in 2005. "Our success in developing and marketing a consistent stream of topical products is gratifying. We continue...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry